Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Patients receiving neflamapimod three times daily demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily.